Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.38 USD | -0.67% | +3.65% | +62.20% |
May. 09 | Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 471M |
---|---|---|---|---|---|
Net income 2024 * | -77M | Net income 2025 * | -138M | EV / Sales 2024 * | - |
Net cash position 2024 * | 185M | Net cash position 2025 * | 59.3M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.37
x | P/E ratio 2025 * |
-3.43
x | Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.55% |
Latest transcript on Larimar Therapeutics, Inc.
1 day | -0.67% | ||
1 week | +3.65% | ||
Current month | +7.11% | ||
1 month | +15.67% | ||
3 months | -42.25% | ||
6 months | +124.32% | ||
Current year | +62.20% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 65 | - | |
Michael Celano
DFI | Director of Finance/CFO | 65 | 20-05-27 |
Noreen Scherer
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Leff
BRD | Director/Board Member | 55 | 20-05-27 |
Frank Thomas
BRD | Director/Board Member | 54 | 20-05-27 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 23-10-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +3.87% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 7.38 | -0.67% | 284,266 |
24-05-16 | 7.43 | -5.59% | 465,595 |
24-05-15 | 7.87 | -0.13% | 165,636 |
24-05-14 | 7.88 | +7.65% | 328,292 |
24-05-13 | 7.32 | +2.81% | 213,961 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.20% | 471M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- LRMR Stock